相似文献
1
Innovative Molecular Target and Therapeutic Approaches in Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis (NAFLD/NASH) 2.0.
Int J Mol Sci. 2022 Jul 18;23(14):7894. doi: 10.3390/ijms23147894.
2
Innovative Molecular Targets and Therapeutic Approaches in Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis (NAFLD/NASH) 3.0.
Int J Mol Sci. 2024 Apr 3;25(7):4010. doi: 10.3390/ijms25074010.
3
New therapeutic strategies in nonalcoholic fatty liver disease: a focus on promising drugs for nonalcoholic steatohepatitis.
Pharmacol Rep. 2020 Feb;72(1):1-12. doi: 10.1007/s43440-019-00020-1. Epub 2020 Jan 8.
4
Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
World J Gastroenterol. 2015 Apr 7;21(13):3777-85. doi: 10.3748/wjg.v21.i13.3777.
5
Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
World J Gastroenterol. 2014 Nov 14;20(42):15539-48. doi: 10.3748/wjg.v20.i42.15539.
6
Potential Therapeutic Application of Estrogen in Gender Disparity of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis.
Cells. 2019 Oct 15;8(10):1259. doi: 10.3390/cells8101259.
7
Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box!
Metabolism. 2019 Dec;101:154001. doi: 10.1016/j.metabol.2019.154001. Epub 2019 Oct 28.
8
[Overview of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis Management].
Yakugaku Zasshi. 2019;139(9):1147-1153. doi: 10.1248/yakushi.19-00011-1.
9
Molecular Mechanisms of Nonalcoholic Fatty Liver Disease (NAFLD)/Nonalcoholic Steatohepatitis (NASH).
Adv Exp Med Biol. 2021;1261:223-229. doi: 10.1007/978-981-15-7360-6_20.
10
Nonalcoholic Liver Disease in Children and Adolescents.
Clin Liver Dis. 2018 Nov;22(4):723-733. doi: 10.1016/j.cld.2018.07.001. Epub 2018 Aug 22.
引用本文的文献
1
Overexpression of Interleukin-8 Promotes the Progression of Fatty Liver to Nonalcoholic Steatohepatitis in Mice.
Int J Mol Sci. 2023 Oct 23;24(20):15489. doi: 10.3390/ijms242015489.
本文引用的文献
1
MCD Diet Rat Model Induces Alterations in Zinc and Iron during NAFLD Progression from Steatosis to Steatohepatitis.
Int J Mol Sci. 2022 Jun 19;23(12):6817. doi: 10.3390/ijms23126817.
2
Smad3 Phospho-Isoform Signaling in Nonalcoholic Steatohepatitis.
Int J Mol Sci. 2022 Jun 3;23(11):6270. doi: 10.3390/ijms23116270.
3
Maternal Pyrroloquinoline Quinone Supplementation Improves Offspring Liver Bioactive Lipid Profiles throughout the Lifespan and Protects against the Development of Adult NAFLD.
Int J Mol Sci. 2022 May 27;23(11):6043. doi: 10.3390/ijms23116043.
4
Soyasapogenol C from Fermented Soybean () Acting as a Novel AMPK/PPARα Dual Activator Ameliorates Hepatic Steatosis: A Novel SANDA Methodology.
Int J Mol Sci. 2022 May 13;23(10):5468. doi: 10.3390/ijms23105468.
5
Lipotoxicity as the Leading Cause of Non-Alcoholic Steatohepatitis.
Int J Mol Sci. 2022 May 5;23(9):5146. doi: 10.3390/ijms23095146.
6
SGLT2 Inhibitors as the Most Promising Influencers on the Outcome of Non-Alcoholic Fatty Liver Disease.
Int J Mol Sci. 2022 Mar 27;23(7):3668. doi: 10.3390/ijms23073668.
7
The Beneficial Effects of Triterpenic Acid and Acteoside in an In Vitro Model of Nonalcoholic Steatohepatitis (NASH).
Int J Mol Sci. 2022 Mar 24;23(7):3562. doi: 10.3390/ijms23073562.
8
Natural Compounds for Counteracting Nonalcoholic Fatty Liver Disease (NAFLD): Advantages and Limitations of the Suggested Candidates.
Int J Mol Sci. 2022 Mar 2;23(5):2764. doi: 10.3390/ijms23052764.
9
The Intestinal Barrier and Its Dysfunction in Patients with Metabolic Diseases and Non-Alcoholic Fatty Liver Disease.
Int J Mol Sci. 2022 Jan 8;23(2):662. doi: 10.3390/ijms23020662.
10
The New Therapeutic Approaches in the Treatment of Non-Alcoholic Fatty Liver Disease.
Int J Mol Sci. 2021 Dec 8;22(24):13219. doi: 10.3390/ijms222413219.
Zotero 插件